Sirna Compositions And Methods For Potently Inhibiting Viral Infection
No Antiviral Regimen Has Been Consistently Successful In Treating H5n1 Virus Infection. We Demonstrate That A Group Of Highly Effective Sirnas Targeting Different H5n1 Viral Genes Shares A Unique Motif, Ggagu/Acucc. We Further Demonstrate That The Effectiveness Of Sirnas Containing This Motif Is Not Sequence Specific. The Results Suggested That The Structure Of The Unique Motif Is Critical In Determining The Potency Of Sirna-Mediated Protective Effects Against Viral Infection And This Potent In Vivo Protection Is Associated With Early Productions Of [Beta]-Defensin And Il-6 Induced By The Motif. Provided Are Methods And Prophylactic And Therapeutic Agents Useful Against Other Viral Infections In Addition To The H5n1 Influenza Virus.
Patent Number: US8664188B2
Application Number: US2009636234A
Inventor: Zheng, Bojian | Sui, Hongyan | Lin, Yongping
Priority Date: 11 Dec 2008
Priority Number: US8664188B2
Application Date: 11 Dec 2009
Publication Date: 4 Mar 2014
IPC Current: A61K003170 | C07H002102 | C07H002104 | C12Q000168
US Class: 514044A | 5360231 | 5360241 | 5360245
Assignee Applicant: Xiangxue Group (Hong Kong) Company Limited
Title: siRNA compositions and methods for potently inhibiting viral infection
Usefulness: siRNA compositions and methods for potently inhibiting viral infection
Summary: For preparing an agent for stimulating interleukin-6 (IL-6) production or for stimulating β -defensin production in a subject; for screening of potential antiviral agents; and as antiviral agents (all claimed), for prophylaxis or treatment of viral infection, preferably by H5N1 influenza virus.
Novelty: New small interfering RNAs useful for prophylaxis or treatment of influenza A virus infection, comprise pentanucleotide motif or reverse motif having specific nucleotide sequence
生物醫學
病原
香港
